A study in men reported that "The reported incidence of penile carcinoma in patients with BXO is 2.6–5.8%". Epidemiology
There is a bimodal age distribution in the incidence of LS in women. It occurs in females with an average age of diagnosis of 7.6 years in girls and 60 years old in women. The average age of diagnosis in boys is 9–11 years old.In men, the most common age of incidence is 21–30. History
In 1875, Weir reported what was possible vulvar or oral LS as "ichthyosis." In 1885, Breisky described kraurosis vulvae. In 1887, Hallopeau described a series of extragenital cases of LS. In 1892, Darier formally described the classic histopathology of LS. In 1900 the concept was formed that scleroderma and LS are closely related, which continues to this day. In 1901, pediatric LS was described. From 1913 to present, the concept that scleroderma is not closely related to LS also was formed. In 1920, Taussig established vulvectomy as the treatment of choice for kraurosis vulvae, a premalignant condition. In 1927, Kyrle defined LS ("white spot disease") as an entity sui generis. In 1928, Stühmer described balanitis xerotica obliterans as a postcircumcision phenomenon. In 1936, retinoids (vitamin A) were used in LS. In 1945, testosterone was used in genital LS. In 1961, the use of corticosteroids started. Jeffcoate presented an argument against vulvectomy for simple LS. In 1971, progesterone was used in LS. Wallace defined clinical factors and the epidemiology of LS.
In 1976, Friedrich defined LS as a dystrophic, not an atrophic condition; "et atrophicus" was dropped. The International Society for Study of Vulvar Disease classification system established that "kraurosis" and "leukoplakia" were no longer to be used. In 1980, fluorinated and superpotent steroids were first used in LS. In 1981, studies into HLA serotypes and LS were published. In 1984, etretinate and acetretin were used in LS. In 1987, LS was linked with Borrelia infection.Lichen sclerosus et atrophicus was first described in 1887 by François Henri Hallopeau. Since not all cases of lichen sclerosus exhibit atrophic tissue, et atrophicus was dropped in 1976 by the International Society for the Study of Vulvovaginal Disease (ISSVD), officially proclaiming the name lichen sclerosus. See also
Lichen planus
List of cutaneous conditions
List of cutaneous conditions associated with increased risk of nonmelanoma skin cancer
List of human leukocyte antigen alleles associated with cutaneous conditions

References
External links
NIAMS – Questions and Answers About Lichen Sclerosus
NIAMS – Fast Facts About Lichen Sclerosus
dermnetnz.org
better medicine
Medscape Reference Author: Jeffrey Meffert, MD; Chief Editor: Dirk M Elston, MDMedical pictures

http://www.dermlectures.com/LecturesWMV.cfm?lectureID=88
https://web.archive.org/web/20070927210529/http://dermis.multimedica.de/dermisroot/de/34088/diagnose.htm
https://web.archive.org/web/20071008130921/http://dermnetnz.org/immune/ls-imgs.html